302 related articles for article (PubMed ID: 27040850)
1. Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study.
Wang Q; Zhao L; Yang X; Wei S; Zeng Y; Mao C; Lin L; Fu P; Lyu L; Li Z; Xiao H
Lung Cancer; 2016 May; 95():39-43. PubMed ID: 27040850
[TBL] [Abstract][Full Text] [Related]
2. A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry.
Gruber K; Kohlhäufl M; Friedel G; Ott G; Kalla C
J Thorac Oncol; 2015 Apr; 10(4):713-6. PubMed ID: 25789835
[TBL] [Abstract][Full Text] [Related]
3. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X
Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.
Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N
Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459
[TBL] [Abstract][Full Text] [Related]
5. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
[TBL] [Abstract][Full Text] [Related]
6. A comparative analysis of immunohistochemistry and fluorescent
Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP
Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679
[TBL] [Abstract][Full Text] [Related]
7. [A standardized protocol for detection of ALK protein expression and gene fusion in lung adenocarcinoma cytologic specimens].
Wang Z; Wu X; Shi Y; Han X; Cheng G; Li L; Mu X; Zhang Y; Cui D; Zhang L; Fan Z; Zhu G; Ma L; Yang L; Di J; Liu D
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):742-8. PubMed ID: 26813592
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.
Wang J; Cai Y; Dong Y; Nong J; Zhou L; Liu G; Su D; Li X; Wu S; Chen X; Qin N; Zeng X; Zhang H; Zhang Z; Zhang S
PLoS One; 2014; 9(7):e101551. PubMed ID: 24992725
[TBL] [Abstract][Full Text] [Related]
9. Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement.
Shan L; Lian F; Guo L; Yang X; Ying J; Lin D
Diagn Pathol; 2014 Jan; 9():3. PubMed ID: 24422905
[TBL] [Abstract][Full Text] [Related]
10. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
11. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.
Lantuejoul S; Rouquette I; Blons H; Le Stang N; Ilie M; Begueret H; Grégoire V; Hofman P; Gros A; Garcia S; Monhoven N; Devouassoux-Shisheboran M; Mansuet-Lupo A; Thivolet F; Antoine M; Vignaud JM; Penault-Llorca F; Galateau-Sallé F; McLeer-Florin A
Eur Respir J; 2015 Jul; 46(1):207-18. PubMed ID: 25929957
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent.
Conklin CM; Craddock KJ; Have C; Laskin J; Couture C; Ionescu DN
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23196275
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.
Demidova I; Barinov A; Savelov N; Gagarin I; Grinevitch V; Stroiakovaski D; Popov M; Laktionov K; Gutorov S; Smolin A; Olshanskaya Y; Obukhova T
Arch Pathol Lab Med; 2014 Jun; 138(6):794-802. PubMed ID: 24878018
[TBL] [Abstract][Full Text] [Related]
14. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
[TBL] [Abstract][Full Text] [Related]
15. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.
Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z
Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706
[TBL] [Abstract][Full Text] [Related]
16. ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm.
Marchetti A; Di Lorito A; Pace MV; Iezzi M; Felicioni L; D'Antuono T; Filice G; Guetti L; Mucilli F; Buttitta F
J Thorac Oncol; 2016 Apr; 11(4):487-95. PubMed ID: 26916631
[TBL] [Abstract][Full Text] [Related]
17. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
[TBL] [Abstract][Full Text] [Related]
18. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
[TBL] [Abstract][Full Text] [Related]
19. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.
Jang JS; Wang X; Vedell PT; Wen J; Zhang J; Ellison DW; Evans JM; Johnson SH; Yang P; Sukov WR; Oliveira AM; Vasmatzis G; Sun Z; Jen J; Yi ES
J Thorac Oncol; 2016 Nov; 11(11):1891-1900. PubMed ID: 27343444
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic lymphoma kinase immunohistochemistry in lung adenocarcinomas: Evaluation of performance of standard manual method using D5F3 antibody.
Jain D; Jangra K; Malik PS; Arulselvi S; Madan K; Mathur S; Sharma MC
Indian J Cancer; 2017; 54(1):209-213. PubMed ID: 29199692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]